N@N

Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market

^{Published on 2009-07-09 05:27:03, Last Modified on 2009-07-09 05:27:09 - Market Wire}
 

 Company seeks partner to commercialize the technology TORONTO, July 9 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced today that it has filed key patent applications based on its novel semen sexing discoveries and that it will now embark on the path to commercialization of this exciting technology. Microbix' recent discoveries should provide a more cost-effective platform for semen sexing and significantly improve yields and quality of the sperm produced compared to the current commercial sexing technology. Both are critical market factors that Microbix believes will allow the company to effectively penetrate and even expand the $3 billion Artificial Insemination (AI) market. Semen sexing is instrumental to the dairy industry due to the growing international demand for female offspring and the negligible value of dairy bull calves. "This market is attractive for its size and the absence of regulatory barriers, and importantly, our technology offers a predictable pathway through development to market," said William J. Gastle, C.E.O. "Now that the intellectual property has been secured, we are focused on finding a strategic partner(s) to help realize Microbix' Semen Sexing Technology's (SST) significant commercial potential and we invite expressions of interest," said Mr. Gastle. Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Mississauga. This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to develop and commercialize SST; non-adoption of SST. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. %SEDAR: 00004220E 

For further information: visit [ www.microbix.com ] or contact: Phil Casselli, President, Microbix Biosystems Inc., (905) 361-8910 x 224; James Long, CFO, Microbix Biosystems Inc., (416) 234-1624 x 265